FindTrial
Sign In

PK/PD study and dose optimization of polymyxin B in critically ill patients

PK/PD study and dose optimization of polymyxin B in critically ill patients

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022231
Enrollment
Unknown
Registered
2019-03-31
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical illness

Interventions

Case series:Polymyxin B

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Aged = 18 years; (2) patients with critically ill infection; (3) The administration of polymyxin B for more than 2 days; (4) At least one steady-state plasma concentration can be obtained; (5) Clinical evaluation or confirmation of Gram-negative bacterial infection.

Exclusion criteria

Exclusion criteria: (1) Patients allergic to polymyxin B; (2) Patients who have recently used an arrow-like muscle relaxant and other neurotoxic drugs that cause respiratory depression; (3) Patients with poor compliance.

Design outcomes

Primary

MeasureTime frame
Blood concentration;Blood;—

Countries

China

Contacts

Public ContactZhang Bikui

the Second Xiangya Hospital, Central South University

bikui_zh@126.com+86 13973116871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026